2005

[36]

Arylpiperazines displaying preferential potency against chloroquine-resistant strains of the malaria parasite Plasmodium falciparum. C.-A. Molyneaux, M. Krugliak, H. Ginsburg, and K. Chibale* Biochemical Pharmacology. 2005, 71, 61-68.

[35]

Economic drug discovery and rational medicinal chemistry for tropical diseases. K. Chibale*. Pure & Applied Chemistry 2005, 77, 1957-1964.

[34]

Reversal of chloroquine resistance in Plasmodium falciparum by 9H-xanthene derivatives. C.-P. Wu, D. A. van Schalkwyk, D. Taylor, P. J. Smith and K. Chibale*. International Journal of Antimicrobial Agents 2005, 26, 170-175.

[33]

Exploiting a basic chemosensitizing pharmacophore hypothesis. Part 1: synthesis and biological evaluation of novel arylbromide and bicyclic chemosensitizers against drug-resistant malaria parasites F. Chouteau, D. Ramanitrahasimbola, P. Rasoanaivo* and K. Chibale*. Bioorg. Med. Chem. Letts., 2005, 15, 3024-3028.

[32]

Design, synthesis and antiplasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. I. Chiyanzu, C. Clarkson, P. J. Smith, J. Lehman, J. Gut. P. J. Rosenthal and K. Chibale*. Bioorg. Med. Chem., 2005, 13, 3249-3261.

[31]

The new permeability pathways: targets and selective routes for the development of new antimalarial agents. H. M. Staines*, J. C. Ellory and K. Chibale. Combinatorial Chemistry and High Throughput Screening 2005, 8, 81-88.